Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T62648 |
DNA-PK-IN-1
|
||
DNA-PK-IN-1 是一种 DNA-PK 的有效抑制剂。DNA 依赖性蛋白激酶 (DNA-PK) 是一种由 Ku70/Ku80 异二聚体和 DNA 依赖性蛋白激酶催化亚基 (DNA-PKcs) 组成的 DNA-PK 酶复合物。DNA-PK-IN-1 具有潜力进行癌症疾病的研究。 | |||
T1826 |
PI3K-IN-1
Voxtalisib Analogue,Voxtalisib (SAR245409, XL765) Analogue,XL765,SAR245409 |
DNA-PK; PI3K | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
PI3K-IN-1 (Voxtalisib Analogue) 是 PI3K 抑制剂,PI3K-IN-1(25 μM) 能够阻断 PI3K/Akt 信号通路。 | |||
T9498 |
BAY-8400
|
DNA-PK | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
BAY-8400是一种具有口服活性、有效和选择性 DNA 依赖蛋白激酶 (DNA-PK) 抑制剂(IC50=81 nM),与靶向α疗法联合使用显示协同疗效。BAY-8400 可用于癌症研究。 | |||
T62034 |
DNA-PK-IN-7
|
||
DNA-PK-IN-7 是有效的 DNA-PK 抑制剂,IC50为 1 nM (WO2021104277A1, compound 5)。 | |||
T61533 | DNA-PK-IN-9 | ||
DNA-PK-IN-9 (also known as compound YK6) is a highly potent inhibitor of DNA-dependent protein kinase (DNA-PK), displaying an IC50 value of 10.47 nM. DNA-PK-IN-9 holds significant potential in anticancer research [1]. | |||
T61633 | DNA-PK-IN-2 | ||
DNA-PK-IN-2 is a highly effective inhibitor of DNA-dependent protein kinase (DNA-PK), which is a complex enzyme composed of Ku70/Ku80 heterodimer and DNA-PK catalytic subunit (DNA-PKcs). With its potential applications in cancer research, DNA-PK-IN-2 demonstrates promise as a valuable tool for studying cancer diseases [1]. | |||
T79165 |
DNA-PK-IN-10
|
DNA-PK | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
DNA-PK-IN-10是一种DNA-PK抑制剂, 主要应用于乳腺癌与非小细胞肺癌的研究。 | |||
T61857 | DNA-PK-IN-4 | ||
DNA-PK-IN-4 (WO2021209055A1, compound 27), an imidazolinone derivative compound, is a highly effective inhibitor of DNA-PK, specifically targeting DNA-PKcs activity. By inhibiting DNA-PKcs, the compound significantly impairs tumor DNA repair mechanisms and triggers apoptosis in cells. With its potential application in cancer research, DNA-PK-IN-4 holds promise for further investigation [1]. | |||
T61370 |
DNA-PK-IN-6
|
||
DNA-PK-IN-6, a robust DNA-PK inhibitor, effectively hampers the activity of DNA-PKcs, thereby significantly impairing the DNA repair mechanism in tumors and instigating apoptosis in cells. Additionally, DNA-PK-IN-6 amplifies the responsiveness of tumor tissues to radiotherapy, overcomes the challenge of drug resistance, and augments its inhibitory impact on a diverse range of solid and hematological tumors[1]. | |||
T61751 |
DNA-PK-IN-3
|
||
DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK. This compound exerts a synergistic effect when combined with radiotherapy and chemotherapy, resulting in enhanced therapeutic outcomes and significant inhibition of tumor growth. Furthermore, DNA-PK-IN-3 demonstrates remarkable efficacy in reducing damage to normal cells, effectively minimizing adverse side effects. Due to these compelling properties, DNA-PK-IN-3 holds great potential for cancer research applications[1]. | |||
T61828 |
DNA-PK-IN-8
|
||
DNA-PK-IN-8(化合物DK1)是一种高效、选择性且口服活性的DNA依赖蛋白激酶 (DNA-PK) 抑制剂,其IC50值为0.8 nM。与Doxorubicin联合应用时,该化合物能在多种癌细胞中展现出协同的抗增殖效应,并能显著地抑制HL-60肿瘤生长。 | |||
T61587 | ATR-IN-15 | ||
ATR-IN-15 (compound 1) is a highly potent and orally active inhibitor of ATR kinase with an IC50 of 8 nM. Additionally, ATR-IN-15 demonstrates inhibitory activity against several targets, including human colon tumor cells LoVo, DNA-PK, and PI3K, with IC50 values of 47, 663, and 5131 nM, respectively [1]. | |||
T75245 | Canfosfamide | ||
Canfosfamide (TLK-286) 是一种谷胱甘肽类似物前体药物,由谷胱甘肽 S-转移酶 P1-1 激活,诱导细胞凋亡 (apoptosis)。Canfosfamide 还抑制 DNA 依赖性蛋白激酶 (DNA-PK) 的催化激酶活性。Canfosfamide 在活化后产生一种抗癌烷基化剂和谷胱甘肽衍生物。Canfosfamide 可用于恶性肿瘤的研究。 | |||
T78756 | Yhhu6669 | HBV | Microbiology/Virology |
Yhhu6669为抗HBV药物,能够抑制HBVDNA。该化合物通过诱导无DNA衣壳的形成,从而抑制HBV复制,且能有效降低AAV/HBV感染小鼠中的HBVDNA及HBcAg水平,展现出优良的药代动力学特性。 |